Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India
Phase 4
Active, not recruiting
- Conditions
- Cervical CancerCervical Precancerous Lesions
- Interventions
- Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Partha Basu
- Target Recruit Count
- 22729
- Registration Number
- NCT00923702
- Locations
- 🇮🇳
All India Institute of Medical Sciences, New Delhi, India
🇮🇳Tata Memorial Center, Tata Memorial Hospital & Cancer Research Inst, Mumbai, Maharashtra, India
🇮🇳MNJ Institute of Oncology & Regional Cancer Center, Hyderabad, Andhra Pradesh, India
© Copyright 2025. All Rights Reserved by MedPath